Having defined BCAR3 as a novel TGFβ/Smad inhibitory molecule, this may account for the relatively low BCAR3 expression levels observed in primary breast tumors associated with worse prognosis and higher levels of disease progression. Here, TGFB1 is linked to breast neoplasm.